SCHEMBL799663

SCHEMBL799663

Cc1ccc(C)c([N+](=O)[O-])n1

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.53
S1PR4 O95977 10/20 0.50
NPC1 O15118 5/20 0.49
RAB9A P51151 4/20 0.49
MAPT P10636 5/20 0.47
LMNA P02545 3/20 0.47
ALOX12 P18054 1/20 0.47
SMN1; SMN2 Q16637 3/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HPGD P15428 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
CTSB P07858 1/20 0.42
CTSH P09668 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2638818 0.81 NPC1 (0.47) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL6785310 0.80 ALDH1A1 (0.46) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL10309700 0.79 MAPT (0.40) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL31121580 0.79 CTSB (0.56) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL28051995 0.79 S1PR4 (0.52) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL10025751 0.79 NPC1 (0.51) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL187124 0.79 CTSB (0.56) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL31129879 0.79 S1PR4 (0.44) ALDH1A1S1PR4NPC1RAB9AMAPT
SCHEMBL31481290 0.79 ALDH1A1 (0.39) ALDH1A1S1PR4MAPTLMNAALOX12
SCHEMBL1700862 0.79 NOS3 (0.48) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9346822-B2 Thienopyrimidine compounds and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-24 US disclosed
US-20140221381-A1 THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-08-07 US disclosed
US-8735401-B2 Thienopyrimidine compounds and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-05-27 US disclosed
US-20120071486-A1 THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071486-A1 THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF GNRHR, KISS1R, NR5A1 ALDH1A1 1567/4885S1PR4 497/4885NPC1 3957/4885
US-20140221381-A1 THIENOPYRIMIDINE COMPOUNDS AND USE THEREOF GNRHR, KISS1R, NR5A1 ALDH1A1 1567/4885S1PR4 497/4885NPC1 3957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.